HCM News and Press, HUTCHMED (China) Limited From 02/28/23

HUTCHMED (China) Limited (HCM) Q4 2022 Earnings Conference Call February 28, 2023, 08:00 AM ET Company Participants Mark Lee - SVP Corporate Finance and Development Weiguo Su - CEO and Chief Scientific Officer Hong Chen - Chief Commercial Officer Johnny Cheng - CFO...

Hutchison China MediTech press release ( NASDAQ: HCM ): FY GAAP EPADS of -$2.13 misses by $0.02 . Revenue of $426.4M (+19.7% Y/Y) beats by $16.62M . Cash, Cash Equivalents and Short-Term Investments were $631.0 million as of December 31, 2022 compared to $1,011.7 mil...

Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of Phase II registration trial of amdizalisib in pat...

Summary With pharma sector lacking in our portfolio, we are looking to add some if we find a good risk/reward situation. HUTCHMED (China) being a part of CK Hutchison Holdings, a huge conglomerate, is developing well. By 2035, it is estimated that 25% of the global population will b...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern S...

Summary HutchMed out-licensed global rights (ex-China) for a colorectal cancer therapy, fruquintinib, to Takeda Pharmaceutical in a deal worth up to $1.13 billion, including $400 million upfront. Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatm...

Takeda ( NYSE: TAK ) signed a licensing agreement with Hutchmed (China) ( NASDAQ: HCM ) to develop and commercialize oral cancer drug fruquintinib outside of mainland China, Hong Kong and Macau. Under the agreement, Takeda will pay $400M upfront, up to $730M in additional pote...

— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS...